[강소기업 줌인] 엑셀세라퓨틱스, 공격적 R&D로 기업가치 재평가 포석

Xcell Therapeutics is strategically transitioning from an R&D-heavy phase to a commercial manufacturing model by scaling its 3rd generation chemically defined media, CellCor™. This shift is significant because the high lock-in effect in the CGT sector ensures long-term revenue stability and market dominance once integrated into global clinical pipelines.